STD Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sexually transmitted diseases (STDs), increasingly termed sexually transmitted infections (STIs) to reflect the broader spectrum including asymptomatic infections, are caused by pathogens transmitted predominantly through sexual contact. The World Health Organization estimates over 1 million STIs are acquired daily globally, with chlamydia, gonorrhea, syphilis, and trichomoniasis collectively affecting over 374 million people per year. HIV infects approximately 1.5 million new people annually, while human papillomavirus (HPV) is the most prevalent viral STI with lifetime prevalence approaching 80% in sexually active adults.

STDs are categorized by pathogen type. Bacterial STDs include: chlamydia (Chlamydia trachomatis) — the most commonly reported STI in developed countries; gonorrhea (Neisseria gonorrhoeae) — characterized by increasing antibiotic resistance including multidrug-resistant strains (MRNG); syphilis (Treponema pallidum) — a systemic infection with four stages; chancroid (Haemophilus ducreyi); and lymphogranuloma venereum (LGV, Chlamydia trachomatis serovars L1-L3, increasingly seen in MSM). Viral STDs include: herpes simplex virus (HSV-1 and HSV-2); HIV/AIDS; HPV (over 100 strains, 40+ genital types); hepatitis B and C; molluscum contagiosum; and Zika virus (sexual transmission documented). Parasitic STDs: trichomoniasis (Trichomonas vaginalis — most common curable STI globally); pubic lice (Phthirus pubis); and scabies (Sarcoptes scabiei) through close physical contact.

Treatment follows pathogen-specific protocols based on CDC STI Treatment Guidelines (2021) and WHO STI Guidelines (2022). Bacterial STDs are curable with antibiotics; viral STDs are managed but not generally cured (except Hepatitis C with direct-acting antivirals); parasitic STDs are curable with antiparasitics. Partner notification and treatment is a cornerstone of STD management to prevent reinfection and community transmission. Prevention includes condom use, vaccination (HPV, hepatitis B), and HIV pre-exposure prophylaxis (PrEP).

STD treatment covers the full spectrum of sexually transmitted pathogens. Chlamydia is commonly asymptomatic (70% of women, 50% of men) but causes urethritis, cervicitis, pelvic inflammatory disease (PID), epididymo-orchitis, and — if untreated — tubal factor infertility and ectopic pregnancy. Treatment: azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days (doxycycline preferred per 2021 CDC guidelines due to lower treatment failure rates with rectal chlamydia).

Gonorrhea presents with urethritis (discharge, dysuria), cervicitis, or proctitis; disseminated gonococcal infection (DGI) causes septic arthritis and skin lesions. CDC 2021 guidelines recommend ceftriaxone 500 mg IM (or 1 g IM if weight >150 kg) single dose as monotherapy — the dual-therapy approach with azithromycin was discontinued due to resistance concerns. Multidrug-resistant gonorrhea (MRNG) is a WHO priority drug-resistant pathogen.

Syphilis treatment varies by stage: primary, secondary, and early latent syphilis — benzathine penicillin G 2.4 million units IM single dose; late latent and tertiary syphilis — benzathine penicillin G 2.4 million units weekly for 3 weeks; neurosyphilis — aqueous crystalline penicillin G IV for 10–14 days. Genital herpes (HSV-2, increasingly HSV-1): first episode — acyclovir 400 mg TID for 7–10 days or valacyclovir 1 g BID for 10 days; suppressive therapy — valacyclovir 500–1,000 mg daily (reduces recurrences by 70–80% and transmission risk by 48%). HIV treatment with antiretroviral therapy (ART) is recommended for ALL HIV-positive individuals regardless of CD4 count, achieving viral suppression in 85–90% of adherent patients and enabling near-normal life expectancy. Hepatitis C is now curable in 95–99% of patients with 8–12 weeks of direct-acting antiviral (DAA) therapy (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir).

STD treatment is required for all confirmed and frequently for syndromically suspected infections in high-risk settings. Syndromic management — empirical treatment based on clinical syndrome without awaiting lab confirmation — is appropriate in resource-limited settings where laboratory confirmation delays treatment and risks onward transmission.

Diagnostic workup for comprehensive STD screening includes: NAAT (nucleic acid amplification testing) for chlamydia and gonorrhea from genital, rectal, and pharyngeal swabs as appropriate for sexual exposure; serological testing for syphilis (RPR/VDRL with confirmatory TPHA/FTA-ABS), HIV (4th generation antigen/antibody combination test), hepatitis B (HBsAg, anti-HBs, anti-HBc), hepatitis C (anti-HCV with HCV RNA confirmation); HSV type-specific IgG serology (when asymptomatic partner status is clinically relevant). Wet mount or NAAT for trichomoniasis. Proctoscopy for proctitis symptoms with anoscopic swabs.

HIV pre-exposure prophylaxis (PrEP) eligibility: HIV-negative individuals at high risk (condomless anal intercourse with partner of unknown or positive status, shared injection equipment, recent STD diagnosis); requires HIV-negative confirmation, adequate renal function (tenofovir-based PrEP), and 3-monthly monitoring. HPV vaccination: ACIP recommends routine vaccination at age 11–12, catch-up through age 26; shared decision-making for ages 27–45. Hepatitis B vaccination for all unvaccinated individuals. Post-exposure prophylaxis (PEP) for HIV: initiated within 72 hours of high-risk exposure, continued 28 days. Partner notification: a legal and public health requirement for bacterial STDs in most jurisdictions; contact tracing services available through public health departments.

STD treatment is pathogen-specific. Evidence-based regimens from CDC and WHO guidelines:

• Chlamydia trachomatis: Doxycycline 100 mg twice daily for 7 days (preferred over azithromycin 1 g single dose due to superior efficacy in rectal chlamydia); test-of-cure at 3–4 weeks in pregnant women. All sexual partners within 60 days must be treated.
• Gonorrhoea (N. gonorrhoeae): Ceftriaxone 500 mg IM single dose (or 1 g if weight >150 kg) per 2021 CDC guidelines. Dual therapy with doxycycline is no longer recommended for uncomplicated gonorrhoea unless chlamydia co-infection is unexcluded. Extended-spectrum cephalosporin resistance is emerging and mandates culture + sensitivity in treatment failures.
• Syphilis: Primary, secondary, and early latent syphilis — benzathine penicillin G 2.4 million units IM single dose. Late latent and cardiovascular syphilis — 3 weekly doses. Neurosyphilis requires aqueous penicillin G IV 18–24 million units/day for 10–14 days. Doxycycline for penicillin-allergic patients (non-pregnant).
• Herpes simplex (HSV-1, HSV-2): Acyclovir 400 mg TID or valacyclovir 500 mg BD for 7–10 days for primary episode. Suppressive therapy (valacyclovir 500 mg once daily) reduces recurrence frequency by 75–80% and transmission risk by 50% in serodiscordant couples.
• HIV: ART (antiretroviral therapy) — recommended for all HIV-positive individuals regardless of CD4 count. Modern regimens (dolutegravir/tenofovir/emtricitabine) suppress viral load to undetectable within 3–6 months, preventing transmission (U=U: Undetectable = Untransmittable). PrEP (pre-exposure prophylaxis) with tenofovir-emtricitabine reduces HIV acquisition by 99% in adherent users.
• HPV: No treatment for the virus itself; treatment directed at lesions. Genital warts — topical podophyllotoxin, imiquimod, trichloroacetic acid, or cryotherapy. Cervical dysplasia managed per colposcopy-guided protocols. HPV vaccination (9-valent Gardasil) prevents infection with 7 high-risk and 2 low-risk HPV types.
• Trichomoniasis: Metronidazole 2 g orally as single dose (men) or 500 mg BD for 7 days (women — superior cure rate). Partner treatment concurrent. Test-of-cure at 3 weeks if symptoms persist.
• Mycoplasma genitalium: Azithromycin resistance now >50% in many regions. Doxycycline 100 mg BD for 7 days then moxifloxacin 400 mg daily for 7 days in treatment failures. Resistance-guided therapy using NAAT with macrolide resistance genotyping is recommended.

Bacterial STD cure rates with appropriate antibiotic therapy are excellent. Chlamydia: cure rate of 95–99% with doxycycline 7-day course or azithromycin single-dose (doxycycline slightly superior for rectal infection). Gonorrhea: uncomplicated urogenital gonorrhea cured in 99% with ceftriaxone 500 mg IM single dose when the infecting strain is ceftriaxone-susceptible. Primary syphilis is cured in 95%+ with a single IM penicillin injection, with RPR titer expected to decline 4-fold by 6–12 months. Trichomoniasis: cure rate 84–98% with metronidazole or tinidazole single-dose or 7-day treatment.

HIV antiretroviral therapy transforms HIV from a fatal disease into a manageable chronic condition. Modern ART regimens (single-tablet regimens: bictegravir/tenofovir/emtricitabine; dolutegravir/abacavir/lamivudine) achieve undetectable viral load (<200 copies/mL) in 85–95% of adherent patients within 6 months, restoring near-normal CD4 counts and life expectancy. Undetectable = Untransmittable (U=U) — persons with HIV on successful ART with undetectable viral load have zero risk of sexually transmitting HIV to partners, enabling HIV-positive individuals to have sexual relationships without transmission risk.

HPV vaccines (Gardasil 9 — covering HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) prevent approximately 90% of cervical cancers, 85% of HPV-related anogenital cancers, and 90% of genital warts. Vaccination before sexual debut provides complete protection against covered strains. Hepatitis C cure with DAA therapy is 95–99% with 8–12 week regimens — one of modern medicine's greatest treatment successes. PrEP reduces HIV acquisition by 99% with perfect adherence (daily oral tenofovir/emtricitabine).

STD treatment is generally well-tolerated, but specific risks warrant awareness. Antibiotic resistance is the dominant challenge in STD treatment. Gonorrhea has demonstrated sequential resistance to penicillins, tetracyclines, fluoroquinolones, and now reduced susceptibility to azithromycin — making ceftriaxone monotherapy the last reliable oral option for most strains globally. WHO classifies Neisseria gonorrhoeae as a high-priority drug-resistant pathogen, with extensively drug-resistant (XDR) gonorrhea strains emerging in multiple countries. Dual antibiotic therapy with ceftriaxone plus azithromycin is now only recommended for confirmed azithromycin-susceptible strains.

Jarisch-Herxheimer reaction occurs in 10–30% of patients treated for early syphilis with penicillin — characterized by fever, rigors, headache, and myalgia within 2–12 hours of first treatment dose. It is not a drug allergy but rather an inflammatory response to dying treponemes. It is self-limiting (resolves in 12–24 hours) and managed with antipyretics; of concern in pregnancy (may cause early labor) and neurosyphilis. Penicillin allergy: 10% of patients report penicillin allergy, though true IgE-mediated allergy is present in only 1–2%. Cross-reactivity with cephalosporins is 2–4% in truly penicillin-allergic patients; skin testing can confirm allergy status. Penicillin-allergic syphilis patients require desensitization for neurosyphilis.

HIV ART: modern regimens are well-tolerated, but initial side effects (nausea, headache, fatigue — typically resolving in 2–4 weeks), potential for drug-drug interactions, and long-term metabolic effects (lipid changes, bone density effects with tenofovir, weight gain with integrase inhibitors) require monitoring. Partner reinfection — the most common cause of treatment failure for bacterial STDs — underscores the importance of simultaneous partner treatment and abstaining from intercourse until all partners are treated and confirmed infection-free.

Post-treatment follow-up is essential for confirming cure, detecting reinfection, and managing complications:

• Test-of-cure: Chlamydia and gonorrhoea — re-testing at 3 months post-treatment recommended (high reinfection rate from untreated partners), not at <3 weeks as nucleic acid amplification tests detect residual DNA. Syphilis — RPR titer monitoring at 6, 12, and 24 months to confirm fourfold titer decline indicating adequate treatment response. HIV viral load at 4 weeks and 3 months post-ART initiation.
• Partner notification: Sexual partner tracing and treatment is the cornerstone of STD control. Electronic partner notification (e.g., inSPOT, TellYourPartner) and expedited partner therapy (EPT — providing treatment to partners without examination) improve partner treatment rates.
• Rescreening for high-risk populations: MSM, sex workers, and HIV-positive individuals should be rescreened every 3 months for gonorrhoea, chlamydia, and syphilis. Annual HIV testing for all sexually active adults is recommended.
• Complication monitoring: Syphilis with neurological symptoms or treatment failure requires CSF examination for neurosyphilis. Pelvic inflammatory disease (PID) caused by gonorrhoea/chlamydia requires 72-hour clinical review to assess treatment response; hospitalization criteria include inability to tolerate oral antibiotics, tubo-ovarian abscess, or failed outpatient therapy.

STD treatment costs are highly variable depending on the infection type, treatment duration, and whether chronic management (HIV, herpes) or acute cure (bacterial STDs) is involved.

Bacterial STD treatment (chlamydia, gonorrhea): In India, treatment with generic antibiotics (doxycycline, ceftriaxone) costs $5–30 for a complete course at government or private clinics; consultation fees $10–50 additional. In USA, acute treatment costs $50–200 including consultation and medication; testing adds $100–400 at commercial labs. NHS in UK provides free STI testing and treatment at GUM (genitourinary medicine) clinics.

HIV antiretroviral therapy (ART): India produces the world's generic ART — brands like Cipla, Aurobindo supply WHO-procured generic regimens globally. Tenofovir/lamivudine/dolutegravir (TLD) generic costs approximately $75–200/year in India through government programs; private cost $200–600/year. In USA, brand ART regimens cost $18,000–50,000/year without insurance; with insurance and patient assistance programs, out-of-pocket costs may be manageable. HIV PrEP: generic tenofovir/emtricitabine in India costs $50–200/year; US brand Truvada/Descovy costs $12,000–20,000/year (generic tenofovir DF/emtricitabine available since 2020 for $6,000–8,000/year in USA).

HPV vaccine (Gardasil 9, 2-dose series for ages <15, 3-dose for 15+): India $100–200 per dose private ($300–600 for series); government-subsidized programs available in some states. USA $200–300 per dose ($500–800 series); covered by insurance for most eligible age groups under ACA. Hepatitis C DAA therapy: India generic sofosbuvir/velpatasvir (Sofosbuvir 400 mg + Velpatasvir 100 mg) costs $200–600 for a 12-week course; USA brand Epclusa costs $24,000 for 12 weeks. Comprehensive STD screening panel: India $50–200 at accredited laboratories; USA $200–800 at commercial labs.

STD prevention is as important as treatment:

• Condom use: Correct and consistent use of male latex condoms reduces HIV transmission by 80–95%, gonorrhoea and chlamydia by 50–70%, and herpes by 30–40% (incomplete protection due to skin-to-skin transmission). Female condoms provide equivalent protection when used correctly.
• Vaccination: HPV vaccine (Gardasil 9) recommended for all individuals 9–26 years; catch-up vaccination 27–45 years in shared decision-making. Hepatitis B vaccine (3-dose series) prevents HBV acquisition. Hepatitis A vaccine recommended for MSM and high-risk travellers. Mpox (monkeypox) vaccine (JYNNEOS) for high-risk individuals.
• PrEP (HIV pre-exposure prophylaxis): Daily oral tenofovir/emtricitabine (Truvada/generic) or injectable cabotegravir every 8 weeks virtually eliminates HIV acquisition risk in adherent high-risk individuals. Recommended for HIV-negative MSM, serodiscordant couples, and high-risk heterosexual individuals.
• Regular screening: Asymptomatic STD screening in high-risk populations (annual for sexually active women <25, pregnant women, MSM) detects infection before complications develop and before onward transmission.